Safety and efficacy of zotarolimus‐eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE‐DIABETES CHINA Study

• DOI: 10.1111/1753-0407.12832
• Publication Date: 2018-08-03T14:11:43Z
• Authors: Zhengbin Zhu; Yongjian Wu; Zhujun Shen; Yawei Xu; Yigang Li; Yan Wang; Xi Su; Bao Li; Tiemin Jiang; Jinfa Jiang; Lefeng Wang; Shenghu He; Xueqi Li; Hongwei Li; Yin Liu; Yujie Zhou; Qiang Tang; Yundai Chen; Weiyi Fang; Li Jiang; Chengzhi Lu; Jincheng Guo; Jianjun Zhang; Shaoliang Chen; Yong Xia; Hongchao Zheng; Bin Wang; Daifu Zhang; Liuliu Feng; Lijiang Tang; Peng Xu; Xuebo Liu; Ruiyan Zhang
• Keywords: Clinical endpoint; Zotarolimus; Target lesion

The RESOLUTE-DIABETES CHINA study was specifically designed to investigate the safety and efficacy of Resolute zotarolimus-eluting stents (ZES; Medtronic, Santa Rosa, CA, USA) in treatment diabetic coronary lesions Chinese population.In all, 945 patients with de novo native type 2 diabetes mellitus were recruited at 32 cardiac centers across mainland implanted ZES. primary endpoint target vessel failure (TVF); secondary endpoints clinical outcomes, namely all-cause death, stroke, bleeding, lesion revascularization (TLR), (TVR), non-TVR, stent thrombosis (ST). follow-up period for all 12 months after procedure.In 933 (98.73%) had months. rate TVF 11.60%, whereas occurrence 5.47%, four (0.43%) having subacute or late ST. There no significant differences rates comparing different HbA1c levels receiving glucose control treatments (all P > 0.05). Patients multivessel higher (95% confidence intervals) than those single-vessel (16.76% [12.10%-22.97%) vs 9.72% [7.79%-12.11%], respectively; = 0.006). without small vessels, bifurcated lesions, chronic total occlusions [Correction added on 17 January 2019, first online publication: second sentence Results section, "TLF" changed "TVF".].Resolute ZES may perform well population, especially poor control, complex certain unfavorable features. Further studies are needed determine why this population.